Citations

Mayo Clinic

Showing 10 of 108523 citations.

Pain intensity and opioid consumption after temporary and permanent peripheral nerve stimulation: a 2-year multicenter analysis
West, Tyler , Hussain, Nasir , Bhatia, Anuj , Kilgore, Anthony E, Palettas, Marilly , Javed, Saba , D’Souza, Ryan S. , ElSaban, Mariam , D'Souza, Ryan S , Bhatia, Anuj , Kilgore, Anthony E., Abdel‐Rasoul, Mahmoud , Javed, Saba

Regional Anesthesia & Pain Medicine | July 26, 2024 | Volume: 50 | Issue: 11 | Pages: 865-872

10.1136/rapm-2024-105704 | PMID 39060006 Get It

Objective Peripheral nerve stimulation (PNS) is an emerging neuromodulation modality, yet there remains limited data highlighting its long-term effectiveness. The objective of this study was to report real-world data on pain intensity and opioid consumption after temporary and permanent PNS for chronic pain up to 24 months postimplantation. Methods A retrospective study was conducted on all patients who received PNS implants at a multi-centered enterprise between January 1, 2014 and February 24, 2022. The two co-primary outcomes were: (1) change in pain intensity (11-point Numerical Rating Scale) from baseline to 12 months postimplant; and (2) comparison of the change in pain intensity between temporary and permanent PNS cohorts 12 months postimplant. Results 126 patients were included in this analysis. Pain intensity significantly decreased 12 months postimplant in the overall cohort (mean difference (MD) −3.0 (95% CI −3.5 to −2.4), p<0.0001). No significant difference in this reduction was identified between temporary and permanent PNS cohorts (MD 0.0 (95% CI −1.1 to 1.0), p=1.00) 12 months postimplantation. Pain intensity significantly decreased in the overall, temporary, and permanent cohorts at all secondary time points (3, 6, and 24 months). No change in daily opioid consumption was observed at 6 and 12 months postimplant in the overall cohort. Conclusion This study found that both temporary and permanent PNS may be effective for reducing pain intensity in patients with chronic pain up to 24 months postimplantation, although no changes in opioid consumption were observed. The decrease in pain intensity was comparable between patients receiving temporary versus permanent implants, highlighting that temporary PNS may achieve long-lasting clinical benefits. However, given the substantial loss to follow-up, further large-scale studies are needed to solidify conclusions about the efficacy of PNS.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Johnson, Douglas B. , Albertini, Mark R. , Barker, Christopher A. , Bateni, Sarah B. , Baumgartner, Joel , Bichakjian, Christopher K. , Chandra, Sunandana , DiMaio, Dominick J. , Dronca, Roxana , Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hyngstrom, John , Karakousis, Giorgos C. , Kendra, Kari , Lange, Julie R., Lanning, Ryan M. , Logan, Theodore F. , Ott, Patrick A. , Ross, Merrick I. , Skitzki, Joseph J. , Smith, Emily , Tsai, Katy K., Wuthrick, Evan , Xing, Yan, McMillian, Nicole R., Espinosa, Sara, Olson, Daniel J. , Swetter, Susan M. , Bhatia, Shailender , Boland, Genevieve M. , Chmielowski, Bartosz , Fields, Ryan C. , Kiuru, Maija H. , Olson, Daniel, Olszanski, Anthony J. , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit R. , Xing, Yan

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 290-298

10.6004/jnccn.2024.0036 | PMID 39019054 Get It

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous ) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Bailey, Janet E., Burstein, Harold J. , Chen, Nan , Chew, Helen K. , Dang, Chau T. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Lyons, Janice A., McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Santa‐Maria, Cesar A. , Schneider, Bryan P. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wei, Mei , Wisinski, Kari B. , Yeung, Kay T. , Schonfeld, Ryan, Telli, Melinda L , Abramson, Vandana G. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Soliman, Hatem Hussein , Young, Jessica S. , Kumar, Rashmi

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 331-357

10.6004/jnccn.2024.0035 | PMID 39019058 Get It

Breast cancer is treated with a multidisciplinary approach involving surgical oncology, radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget’s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of systemic therapy (preoperative and adjuvant) options for nonmetastatic breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org .
The COVID‐19 pandemic as a modifier of DGBI symptom severity: A systematic review and meta‐analysis
Kulin, Dmitrii , Shah, Ayesha , Fairlie, Thomas, Wong, Reuben K. , Fang, Xiucai , Ghoshal, Uday C. , Kashyap, Purna , Mulak, Agata , Lee, Yeong Yeh , Talley, Nicholas J. , Jones, Michael , Holtmann, Gerald , Talley, Nicholas J. , Kashyap, Purna C , Koloski, Natasha , Jones, Michael P , Holtmann, Gerald J , Ghoshal, Uday C , Mulak, Agata , Lee, Yeong Yeh

Neurogastroenterology & Motility | July 26, 2024 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/nmo.14878 | PMID 39056447 Get It

AbstractBackgroundThis SRMA reviewed and assessed the changes in the severity of disorders of gut‐brain interaction (DGBI) symptoms during the COVID‐19 pandemic, and evaluated factors associated with symptom severity changes.MethodsElectronic databases were searched until February 2024, for articles reporting on changes in symptom severity in DGBI patients during the COVID‐19 pandemic. The proportion of DGBI patients who reported a change in their symptom severity were pooled using a random‐effects model, and subgroup analyses were conducted to assess the effect of socio‐cultural modifiers on symptom severity in DGBI.Key ResultsTwelve studies including 3610 DGBI patients found that 31.4% (95% CI, 15.9–52.5) of DGBI patients experienced symptom deterioration, while 24.3% (95% CI, 10.2–47.5) experienced improvement. Countries with high gross domestic product (GDP) had a 43.5% (95% CI, 16.3–75.2) likelihood of symptom deterioration, compared to 9.2% (95% CI, 1.4–42.2) in lower GDP countries. Similarly, countries with low COVID fatality rates had a 60.1% (95% CI, 19.7–90.3) likelihood of symptom deterioration, compared to 18.3% (95% CI, 7.8–36.9) in higher fatality rate countries. Countries with lenient COVID policies had a 58.4% (95% CI, 14.1–92.3) likelihood of symptom deterioration, compared to 19% (95% CI, 8.2–38.1) in countries with stricter policies. Patients in high vaccine hesitancy countries had a 51.4% (95% CI, 19.5–82.2) likelihood of symptom deterioration, compared to 10.6% (95% CI, 2.7–33.4) in low vaccine hesitancy countries.Conclusions & InferencesThis meta‐analysis reveals that a significantly higher proportion of DGBI patients experienced deterioration of symptoms during the COVID‐19 pandemic. Various sociocultural, economic and environmental factors potentially modify the effects of the COVID‐19 pandemic on DGBI.
Correlations of Socioeconomic and Clinical Determinants with United States County‐Level Stroke Prevalence
Stulberg, Eric , Schneider, Andrea L.C. , Sarpong, Daniel F. , Wong, Ka-Ho , Sheth, Kevin N. , Stulberg, Eric L , Lisabeth, Lynda , Schneider, Andrea L C , Harris, Benjamin R.E., Sheth, Kevin N , Wong, Ka-Ho , Skolarus, Lesli E. , Kershaw, Kiarri N. , Zheutlin, Alexander R. , Harris, B. , Havenon, Adam de

Annals of Neurology | July 26, 2024 | Volume: 96 | Issue: 4 | Pages: 739-744

10.1002/ana.27039 | PMID 39056317 Get It

Socioeconomic status (SES) is a multi‐faceted theoretical construct associated with stroke risk and outcomes. Knowing which SES measures best correlate with population stroke metrics would improve its accounting in observational research and inform interventions. Using the Centers for Disease Control and Prevention's (CDC) Population Level Analysis and Community Estimates (PLACES) and other publicly available databases, we conducted an ecological study comparing correlations of different United States county‐level SES, health care access and clinical risk factor measures with age‐adjusted stroke prevalence. The prevalence of adults living below 150% of the federal poverty level most strongly correlated with stroke prevalence compared to other SES and non‐SES measures (correlation coefficient = 0.908, R2 = 0.825; adjusted partial correlation coefficient: 0.589, R2 = 0.347). ANN NEUROL 2024;96:739–744
Postnatal Cardiometabolic Health After Metformin Use in Gestational Diabetes: A Secondary Analysis of the EMERGE Trial
Dunne, Fidelma , Newman, Christine , Alvarez‐Iglesias, Alberto , O’Shea, Paula , Gillespie, Paddy , O’Donnell, Martin , Smyth, Andrew , Gillespie, Paddy , Egan, Aoife, O'Shea, Paula M , Dunne, Fidelma P , Devane, Declan , Egan, Aoife M. , Newman, Christine

The Journal of Clinical Endocrinology & Metabolism | July 26, 2024 | Volume: 110 | Issue: 5 | Pages: e1566-e1572

10.1210/clinem/dgae522 | PMID 39056256 Get It

Abstract Aim Women with gestational diabetes mellitus (GDM) display adverse lifetime cardiometabolic health. We examined whether early metformin in GDM could impact cardiometabolic risk factors postpartum. Methods EMERGE, a double-blind, placebo-controlled trial, randomized pregnancies 1:1 to placebo or metformin at GDM diagnosis and followed participants from randomization until 12 ± 4 weeks postpartum. In total, 478 pregnancies were available for postpartum maternal assessment, 237 and 241 assigned to metformin and placebo respectively. Weight (kg), body mass index (BMI) (kg/m2), waist circumference (cm), and blood pressure (mmHg) were measured, infant feeding method documented, and blood specimens drawn for a 75-gram oral glucose tolerance test, fasting insulin, C-peptide, and lipid analysis. Results Despite similar weight and BMI at trial randomization, participants receiving metformin had significantly lower weight (79.5 ± 15.9 vs 82.6 ± 16.9 kg; P = .04) and BMI (29.3 [5.6] vs 30.5 [5.4]; P = .018) at the postpartum visit. However, no difference in weight change from randomization to 12 weeks postpartum was observed between metformin and placebo groups. Overall, 29% (n = 139) of the cohort met criteria for prediabetes or diabetes, with no positive impact with metformin. There were also no differences in measurements of insulin resistance, blood pressure, or lipids between groups. Conclusion Early metformin use in GDM did not impact important cardiometabolic parameters in the early postpartum period despite significant benefits in weight gain and insulin use in pregnancy.
Granulomatosis with polyangiitis with and without antineutrophil cytoplasmic antibodies: a case-control study
Falde, S., Sethi, Sanjeev , Fervenza, Fernando C. , Baqir, Misbah , Falde, Sam, Sethi, Sanjeev , Fervenza, Fernando C , Moura, Marta Casal , Specks, Ulrich

Rheumatology | July 26, 2024 | Volume: 63 | Issue: 12 | Pages: 3279-3288

10.1093/rheumatology/keae379 | PMID 39067044 Get It

Abstract Objective ANCA-negative granulomatosis with polyangiitis (GPA) remains a diagnosis of exclusion. Clinical differences between patients with ANCA-negative vs ANCA-positive GPA have not been analysed in sizable case-control studies, and the effects of ANCA-seroconversion from negative to positive are not well documented. Methods A single-centre, sex and age matched case-control study evaluated ANCA-negative vs ANCA-positive GPA from 1 January 1996 to 31 December 2015. Patients who experienced seroconversion were the subject of a case-crossover study. Clinical data and outcomes were retrieved from electronic medical records. Results ANCA-negative GPA was identified in 110 patients; 65% were female; median age was 55 (IQR 39–65) years at time of diagnosis. Disease severity was milder in ANCA-negative GPA (BVAS/WG = 2 vs 6, P &lt; 0.001). Mucous membranous/eye manifestations were more frequent in ANCA-negative GPA. General symptoms, pulmonary and renal involvement were more frequent in ANCA-positive GPA. Patients with ANCA-positive GPA relapsed more over 60 months (21.8% vs. 9.1%, P = 0.009) compared with ANCA-negative GPA and had shorter time to event (P = 0.043). Patients with general manifestations, BMI &gt; 30kg/m2 and necrotizing granulomatous inflammation were more likely to relapse. The 16 patients who seroconverted into ANCA-positive during follow-up had higher mean BVAS/WG at time of diagnosis (P &lt; 0.001) and increased incidence of relapses (P = 0.004) after seroconversion. Necrotizing granulomatous inflammation on biopsy in ANCA-negative GPA patients was identified as a risk factor for subsequent seroconversion to ANCA-positivity. Conclusion Patients with ANCA-negative GPA have milder disease and a lower frequency of relapse than those with ANCA-positive GPA. ANCA appearance portended higher disease severity and an increased frequency of relapses.
Letter: Thrombosed Posterior Inferior Cerebellar Artery Aneurysm Mimicking a Medulla Oblongata Cavernous Malformation: 2-Dimensional Operative Video
Maroufi, Seyed Farzad , Turcotte, Evelyn L. , Bendok, Bernard R. , Bendok, Bernard R

Operative Neurosurgery | July 26, 2024 | Volume: 27 | Issue: 3 | Pages: 403-404

10.1227/ons.0000000000001296 | PMID 39057916 Get It

Non-Invasive Prediction of Pulmonary Vascular Disease-Related Exercise Intolerance and Survival in Non-Group 1 Pulmonary Hypertension
Reddy, Yogesh N.V. , Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Mathai, Stephen C. , Group, and the PVDOMICS Study, DuBrock, Hilary, Nishimura, Rick , Mathai, Stephen C , DuBrock, Hilary M. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Rosenzweig, Erika B. , Mukherjee, Monica , Tang, W.H. Wilson , Borlaug, Barry A. , Frantz, Robert P. , Group, and the PVDOMICS Study

European Journal of Heart Failure | July 26, 2024 | Volume: 26 | Issue: 11 | Pages: 2323-2336

10.1002/ejhf.3396 | PMID 39058211 Get It

Abstract Aims The clinical utility of pulmonary hypertension (PH) risk scores in non-group 1 PH with pulmonary vascular disease (PVD) remains unresolved. Methods and results We utilized the prospective multicenter PVDOMICS cohort with group 2, 3, 4 or 5 PH-related PVD and calculated group 1 PH risk scores (REVEAL 2.0, REVEAL Lite 2, French registry score and COMPERA 2). The c-statistic to predict death was compared separately in (i) pre-capillary PH groups 3/4/5, and (ii) combined post- and pre-capillary PH group 2. Exercise right heart catheterization reserve, ventricular interdependence and right ventricular–pulmonary artery (RV-PA) coupling were compared across risk categories. Among 449 individuals with group 3/4/5 PH, the REVEAL 2.0 risk score had the highest c-statistic for predicting death (0.699, 95% confidence interval [CI] 0.660–0.737, p &lt; 0.0001) with comparable performance using the simpler REVEAL Lite 2 score (0.695, 95% CI 0.656–0.734, p &lt; 0.0001). The French and COMPERA 2 risk scores were also predictive of mortality, but performance of both was statistically inferior to REVEAL 2.0 (c-statistic difference −0.072, 95% CI −0.123 to −0.020, p = 0.006, and −0.043, 95% CI −0.067 to −0.018, p = 0.0007, respectively). RV function and RV-PA coupling measures were prognostic in isolation, but did not add incremental value to REVEAL (p &gt; 0.50 for all). Findings were similar in patients with group 2 PH (n = 239). Stratification by the REVEAL Lite 2 score non-invasively identified non-group 1 PH with more advanced PVD with worse exercise capacity, RV-PA uncoupling, ventricular interdependence and impaired cardiac output reserve (p &lt; 0.05 for all). Conclusions Non-invasive REVEAL risk predicts mortality in non-group 1 PH without incremental prognostic value from detailed RV function or RV-PA coupling assessment. Baseline REVEAL Lite 2 risk stratification non-invasively identifies greater pulmonary vascular dysfunction and right heart-related exercise limitation, which may help guide patient selection for targeted pulmonary vascular therapies in non-group 1 PH.
Over Flexing of the WATCHMAN FLX Muscles in the Real World
Alkhouli, Mohamad , Alkhouli, Mohamad

Circulation: Cardiovascular Interventions | July 26, 2024 | Volume: 17 | Issue: 9 | Pages: No page available

10.1161/circinterventions.124.014465 | PMID 39056182 Get It